Lurbinectedin is not a type of immunotherapy. It is a chemotherapy drug that is used to treat small cell lung cancer (SCLC) [3]. Lurbinectedin works by preventing cancer cells from dividing and growing [1].

Immunotherapy, on the other hand, is a type of cancer treatment that uses the body's immune system to fight cancer cells. It works by either stimulating the immune system to attack cancer cells or by using man-made immune system proteins to target cancer cells [3].

While both lurbinectedin and immunotherapy are used to treat SCLC, they are not interchangeable. Lurbinectedin is used in combination with other chemotherapy drugs to treat SCLC that has relapsed or is resistant to other treatments [2]. Immunotherapy, on the other hand, is used to treat SCLC that has spread or come back after initial treatment [3].

In conclusion, lurbinectedin is not a type of immunotherapy and cannot be used in all types of immunotherapy. It is a chemotherapy drug used to treat SCLC that has relapsed or is resistant to other treatments. Immunotherapy, on the other hand, is a different type of cancer treatment that uses the body's immune system to fight cancer cells and is used to treat SCLC that has spread or come back after initial treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.onclive.com/view/navigating-newfound-options-in-sclc-with-immunotherapy-and-lurbinectedin
[3] https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/chemotherapy.html